REG - Tissue Regenix Group - CFO joins Board

Tissue RegenixAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251017:nRSQ7496Da&default-theme=true

RNS Number : 7496D  Tissue Regenix Group PLC  17 October 2025

 Tissue Regenix Group plc

('Tissue Regenix' or the 'Group')

 

CFO joins Board

 

Tissue Regenix plc (AIM: TRX), the regenerative medical devices company,
confirms that further to the announcement made on Thursday 16 October
(https://www.londonstockexchange.com/news-article/TRX/update-re-fy24-h125-restatement-board-changes/17280929)
, Kirsten Lund, CFO, has joined the board with immediate effect.

 

Additional Disclosures Required under the AIM Rules for Companies

In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Kirsten
Mary Lund (aged 41) holds 113,557 Tissue Regenix shares. There is no further
information to be disclosed in respect of the above appointment pursuant to
Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

For more information:

 

 Tissue Regenix Group plc                                              www.tissueregenix.com (http://www.tissueregenix.com)
 Jay LeCoque, Executive Chairman                                       via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                                Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com
 Alice Woodings / Paul McManus      Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKQLFFEBLFFBZ



            Copyright 2019 Regulatory News Service, all rights reserved